Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Wildbiftek who wrote (5635)	1/15/2020 10:56:31 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

IMGN has openly stated they'd like a ROW partnership for IMGN853 either keeping all of North America, or at least the U.S. totally to themselves. That's what I would like to see, and I certainly hope IMGN can achieve that. Over the years IMGN has often totally monitized products which gave them up front funding for other products, but no long term prospect for earnings. I frankly believe much of SGEN's success occurred because they sold lots of shares when the share price was moderately high, so they had more than adequate funds while IMGN didn't, and often dilution occurred at lower prices which really hurt the stock if they didn't have the ability to monitize other products. I believe a ROW partnership could come at any time, I just hope that IMGN doesn't cave in and give a substantial percentage of the U.S. market to a partner as well. Gary